Spark Therapeutics (NASDAQ:ONCE) had its price objective lifted by SunTrust Banks to $113.00 in a research report issued to clients and investors on Thursday, January 4th, The Fly reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. SunTrust Banks’ price objective suggests a potential upside of 91.66% from the company’s previous close. SunTrust Banks also issued estimates for Spark Therapeutics’ FY2022 earnings at $7.91 EPS.

A number of other analysts have also issued reports on ONCE. Barclays initiated coverage on Spark Therapeutics in a research note on Wednesday, September 6th. They set an “overweight” rating and a $104.00 price objective on the stock. Royal Bank of Canada initiated coverage on Spark Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $100.00 price objective on the stock. Goldman Sachs Group reiterated a “buy” rating and set a $111.00 price objective on shares of Spark Therapeutics in a research note on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating and set a $105.00 price objective (up from $94.00) on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Finally, Jefferies Group reiterated a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, October 10th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and seventeen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $75.18.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded down $0.42 on Thursday, hitting $58.96. The company’s stock had a trading volume of 172,131 shares, compared to its average volume of 876,542. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75. The company has a market capitalization of $2,142.25, a price-to-earnings ratio of -8.17 and a beta of 3.14.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. During the same quarter in the previous year, the firm posted ($1.07) earnings per share. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. equities analysts forecast that Spark Therapeutics will post -7.55 earnings per share for the current fiscal year.

In other news, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the completion of the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $71.54, for a total value of $1,430,800.00. Following the completion of the transaction, the chief executive officer now owns 250,000 shares of the company’s stock, valued at $17,885,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,827 shares of company stock valued at $3,118,519. 7.30% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its holdings in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics during the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA boosted its holdings in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares during the period. Pacad Investment Ltd. boosted its holdings in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in Spark Therapeutics during the 3rd quarter valued at about $225,000. Hedge funds and other institutional investors own 95.30% of the company’s stock.

WARNING: This report was first published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.mareainformativa.com/suntrust-banks-raises-spark-therapeutics-once-price-target-to-113-00-updated-updated-updated/126784/.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

The Fly

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.